NUVL earnings analysis
What we found in NUVL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Nuvalent, Inc. reported a net loss of $109.3 million in Q1 2026, with a diluted EPS loss of $(1.39), compared to a loss of $(1.18) from Q1 2025. The company's operating expenses increased to $119.4 million, driven by research and development efforts, which rose by $9.2 million year-over-year. Management emphasized continued commitment to advancing key drug candidates with two New Drug Applications pending by late 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Increased R&D Focus
- R&D expenses rose to $83.6 million in Q1 2026 from $74.4 million in Q1 2025.
- Significant Cash Reserves
- As of March 31, 2026, Nuvalent reported cash, cash equivalents, and marketable securities of $1.3 billion.
- Pending New Drug Applications
- The FDA has accepted NDAs for zidesamtinib and neladalkib, with action dates in September 2026.
- Higher General Expenses
- General and administrative expenses increased to $35.8 million in Q1 2026 from $20.4 million in Q1 2025.
- Regulatory Milestones
- The company plans further submissions for zidesamtinib in the second half of 2026.
- Increased Operating Expenses
- Total operating expenses for Q1 2026 climbed to $119.4 million versus $94.8 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn
- Net loss for Q1 2026 was $109.3 million, raising concerns about long-term sustainability.
- Regulatory Approval Risks
- The reliance on FDA approvals for two key products poses risks if approvals are delayed or denied.
- Dependence on Third-Party Relationships
- The reliance on contract manufacturers and CROs increases operational risks should they fail to deliver.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.39
What they said about what is next.
Management affirms focus on regulatory milestones, with no numeric guidance provided.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Nuvalent is a clinical-stage oncology biotech focused on selective, brain-penetrant small-molecule kinase inhibitors (lead programs zidesamtinib/NVL-520 and neladalkib/NVL-655). The filing highlights major clinical and…
- 10-Q · August 8, 2024
- Nuvalent reported a widening loss in Q2: net loss of $57.2M (EPS -$0.88) versus $29.1M (EPS -$0.51) in Q2 2023, driven by sharply higher R&D and G&A spend. The company holds substantial liquid resources — cash $77.7M…
- 10-Q · May 9, 2024
- Nuvalent remains a pre-commercial, single-segment clinical-stage biopharma with no product revenue and widening losses in Q1 2024. Net loss increased to $44,482 thousand (‑$0.69 per share) versus $25,192 thousand…
- 10-Q · August 10, 2023
- Nuvalent reported a Q2 net loss of $29,090 thousand (EPS -$0.51) on no product revenue, driven by higher R&D and G&A spending. Cash and marketable securities total $431,239 thousand ($70,872 cash; $360,367 marketable…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NUVL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever